Chemotherapy of metastatic seminoma

Schuette, Jochen; Niederle, N.; Scheulen, M. E.; Seeber, S.; Schmidt, C. G.

doi:10.1038/bjc.1985.67

Cited by 28 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in contrast to patients with NSGCT where there is no apparent excess of second testicular tumours (Duncan & Munro, 1985). Effective chemotherapy is now available for disseminated seminoma (Schuette et al, 1985;Peckham et al, 1985). In the study from the Royal Marsden Hospital (Peckham et al, 1985) It is now considered reasonable not to treat the retroperitoneum prophylactically in patients with Stage I NSGCT and enter these patients in surveillance studies (Peckham et al, 1983;.…”

Section: Methodsmentioning

confidence: 99%

“…Prophylactic radiotherapy, for example to the mediastinum and supraclavicular fossa in patients with nodal disease below the diaphragm, has been widely used. It is now apparent that seminomas are as sensitive to cytotoxic chemotherapy as are the nonseminomatous tumours (Einhorn & Williams, 1980;Ball et al, 1982;Schuette et al, 1985). This, together with improvements in diagnostic imaging, and a desire to minimize the morbidity of therapy has prompted re-evaluation of treatment policies for seminoma of the testis (Oliver et al, 1984).…”

mentioning

confidence: 99%

See 1 more Smart Citation

The management of testicular seminoma: Edinburgh 1970-1981

Duncan¹,

Munro²

1987

Br J Cancer

View full text Add to dashboard Cite

One hundred and fifty two patients with seminoma of the testis presenting to a regional centre between 1970 and 1981 have been reviewed. One hundred and forty three of these patients were treated primarily with radiotherapy. The actuarial survival of all 152 patients was 84.4% at 5 years and 83.3% at 10 years. The following factors significantly influenced survival: clinical stage; T-stage of the primary tumour; date of first treatment. Patients treated after 1979 had a better prognosis than patients treated before 1973. A group of patients with an actuarial survival of 100% at 5 years could be identified: they were in clinical stage I after lymphography and had T1 primary tumours. We could find no clear relationship between tumour size, duration of symptoms and clinical stage at presentation. We conclude that radiation therapy still has an important role to play in the management of seminoma of the testis. We recommend prophylactic retroperitoneal irradiation for patients in clinical stage I, primary treatment with radiotherapy for patients in clinical stages IIA and IIB, and primary treatment with chemotherapy for patients in clinical stages IIC, III and IV.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

The management of testicular seminoma: Edinburgh 1970-1981

Duncan¹,

Munro²

1987

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Pure seminoma re quires radiotherapy in stages I, Ha, and lib; whereas stages lie (bulky disease), III, and IV, as well as nonseminomatous tumors are primarily treated by chemotherapy [9,23,24], ß-hCG and AFP are helpful markers for distin guishing between seminomatous and nonseminomatous tumors. ß-hCG, a glycoprotein, may be synthesized in both syncytiotrophoblastic giant cells and undifferen tiated teratomas, whereas AFP is produced by nonsemi nomatous tumors only [14,[25][26][27][28][29]36], Low ß-hCG serum levels are seen in both seminoma tous and nonseminomatous testicular cancer (< 200 IU/1).…”

Section: Measurement Of Tumor Markersmentioning

confidence: 99%

Role of Human Chorionic Gonadotropin in Patients with Pure Seminoma

Rüther¹,

Rothe²,

Grunert³

et al. 1994

Eur Urol

View full text Add to dashboard Cite

“…Other groups have failed to show an advantage by such a policy (Peckham et al, 1985& Schuette et al, 1985 and this series suggests an improved survival for those patients who received such management. However, this may be because the group is pre-selected and longer follow-up is necessary to assess whether radiotherapy offers an advantage.…”

Section: Discussionmentioning

confidence: 95%

“…Oliver (1984) using PVB obtained a response of 10/12 patients (83%) and with cis-platin as a single agent 10/14 patients (71%); the results in this series were less favourable if the patients had had prior irradiation. Schuette et al (1985) using a combination PVB+adriamycin observed a response of 25/28 (89%) and 23 (82%) of these patients are subsequently disease free with a median followup of 28 months. Loehrer et al (1987) in a recent series of 60 patients treated with PVB + adriamycin obtained a complete response in 41 patients (60%) and 37 of these are currently disease free.…”

Section: Discussionmentioning

confidence: 99%

The treatment of advanced seminoma with chemotherapy and radiotherapy

Wilkinson

Read²,

Magee³

1988

Br J Cancer

View full text Add to dashboard Cite

Between 1979 and 1984 thirty-seven patients were treated with combination chemotherapy for metastatic seminoma; 27 of these had relapsed following initial radiotherapy for stage I and IIA disease and 10 patients with stage IIB-IV disease received chemotherapy de novo followed by radiotherapy to sites of bulk disease. Treatment consisted of either a cis-platinum containing combination (25 patients), or cyclophosphamide and etoposide (12 patients). The overall survival of all patients at 5 years was 49%, 34 patients were assessable for response; a CR was obtained in 8 (24%) and a GPR in 19 (56%), the 5 year survival of this group being 66% at 5 years. No difference in survival was seen in relation to age, previous irradiation, serum HCG or LDH; bulk disease however, was an adverse prognostic factor. Survival was similar for both chemotherapy schedules but neutropenia and life-threatening sepsis was less with the cyclophosphamide etoposide combination.

show abstract

Chemotherapy of metastatic seminoma

Cited by 28 publications

References 19 publications

The management of testicular seminoma: Edinburgh 1970-1981

The management of testicular seminoma: Edinburgh 1970-1981

Role of Human Chorionic Gonadotropin in Patients with Pure Seminoma

The treatment of advanced seminoma with chemotherapy and radiotherapy

Contact Info

Product

Resources

About